Charles Russell Speechlys has advised Emergex Vaccines Holding Limited on the deal. Emergex is a UK-based biotechnology company and pioneers of developing synthetic ‘set point’ vaccines…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
